Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Targeted Fluorescent-Imaging Compound Detects Viable Cancer Cells

By LabMedica International staff writers
Posted on 19 Jan 2009
A fluorescent-imaging compound is turned on only when it is inside a living cell and stops fluorescing when the cell dies or becomes damaged. More...
The compound can be engineered to target specific types of cancer cells.

The new compound enabled scientists to visualize viable breast cancer cells that have spread to the lungs in mice. The compound binds to a protein called HER2, which is found on the surface of some breast cancer cells, and it glows, or fluoresces, only when taken into living cells. This method of targeting and activation allowed the scientists to detect specific types of live cancer cells in a mouse model of breast cancer.

Previously developed fluorescent compounds that are activated inside the body's cells have the limitation that once turned on they continue to fluoresce even after they diffuse to new locations. This makes it very difficult to distinguish viable tumor cells from normal tissue, dead, or damaged tumor cells.

The investigation took place at the National Cancer Institute (NCI), part of the US National Institutes of Health (Bethesda, MD, USA) and in Japan. The scientific team that created the imaging compound was led by Hisataka Kobayashi, M.D., Ph.D., from NCI's Center for Cancer Research (CCR), in collaboration with Yasuteru Urano, Ph.D., from the University of Tokyo (Japan).

"These [fluorescing-imaging] compounds may allow clinicians to monitor a patient's response to cancer therapy by allowing them to visualize whether a drug hits its target and whether hitting the target leads to shrinkage of the tumor," said Dr. Kobayashi. He added, "Our design concept is very versatile and can be used to detect many types of cancer. Unlike other activatable fluorescent compounds, our compound consists of a targeting agent and a fluorescing agent that act independently. We can target the fluorescing agent to different types of cancer cells by using any antibody or molecule that is internalized by the targeted cells after it binds to the cell's surface proteins."

The new compound was described online in Nature Medicine on December 7, 2008.

Related Links:

US National Institutes of Health
University of Tokyo



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.